VirTus develops new COVID-19 serology testing service

We are delighted to announce our new testing service for COVID-19

Click to find out more

About us

Our Services

Pre-clinical studies

Contact

Follow us

Contact

Our clients

We partner with a range of clients from large pharmaceutical companies to biotechs to assist them in the development of new medicines for respiratory diseases.

Infection rate

The overall infection rate of our current stock of rhinovirus is 82% in asthmatics, COPD and healthy volunteers.

Get in touch

Want to find out more how we can help you develop the next block-buster medicine in asthma or COPD? Get in touch.